Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a well-established healthcare company with a solid track record in the molecular diagnostics industry. The company has a diverse portfolio of proprietary tests that assist physicians in diagnosing and treating urologic cancers, making it a key player in the personalized medicine sector. Despite recent challenges, including a recent offering of $20M and the discontinuation of its Resolve UTI test, MDxHealth has remained focused and has a clear strategy for growth, including potential partnerships and acquisitions. With a strong management team and potential for significant revenue growth, MDxHealth is well positioned for long-term success.

Bears say

MDxHealth is a leader in the molecular diagnostics space, but we remain cautious due to recent setbacks in their Resolve UTI test and slower than expected volume and reimbursement growth. Their recent ExoDx conversion may provide a boost in liquid-based volumes, and they have potential synergies from the acquisition of Exosome Diagnostics, but risks to our target price remain including slower growth and potential commercial execution issues. Additionally, their financials show tight cash flow and reliance on debt, as well as ongoing payments to Exact Sciences.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.